[{"id":"29889af3-ae43-4e06-bdfc-acec22c139fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198867","created_at":"2025-10-04T08:02:56.736Z","updated_at":"2025-10-04T08:02:56.736Z","phase":"Phase 1","brief_title":"A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT07198867","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-30"},{"id":"5de3ae22-f200-40ed-bea2-6427c55b3ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984328","created_at":"2025-06-07T14:42:38.975Z","updated_at":"2025-06-07T14:42:38.975Z","phase":"Phase 2","brief_title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","source_id_and_acronym":"NCT06984328","lead_sponsor":"Genmab","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2029","study_completion_date":" 07/15/2029","last_update_posted":"2025-06-03"},{"id":"736082c4-cb8f-4038-ae24-2c9486718043","acronym":"BP41072","url":"https://clinicaltrials.gov/study/NCT04077723","created_at":"2021-01-18T19:58:08.759Z","updated_at":"2025-02-25T13:39:56.985Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04077723 - BP41072","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-21"},{"id":"39739443-27b5-47de-9366-d6dcb750b600","acronym":"SGNBB228-001","url":"https://clinicaltrials.gov/study/NCT05571839","created_at":"2022-10-07T13:59:56.834Z","updated_at":"2025-02-25T14:09:10.779Z","phase":"Phase 1","brief_title":"A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT05571839 - SGNBB228-001","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046049"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 01/03/2023","start_date":" 01/03/2023","primary_txt":" Primary completion: 04/19/2027","primary_completion_date":" 04/19/2027","study_txt":" Completion: 04/18/2028","study_completion_date":" 04/18/2028","last_update_posted":"2025-02-19"},{"id":"59306281-9d17-43db-95fc-ecad547b1392","acronym":"","url":"https://clinicaltrials.gov/study/NCT05719558","created_at":"2023-02-09T16:00:40.694Z","updated_at":"2025-02-25T14:03:18.450Z","phase":"Phase 1","brief_title":"A Study of ASP1002 in Adults for Treatment of Solid Tumors","source_id_and_acronym":"NCT05719558","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1002"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"279f72d7-b141-456e-a82c-b2efb50e3de3","acronym":"BT7480-100","url":"https://clinicaltrials.gov/study/NCT05163041","created_at":"2021-12-20T16:53:57.547Z","updated_at":"2025-02-25T16:53:58.735Z","phase":"Phase 1/2","brief_title":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","source_id_and_acronym":"NCT05163041 - BT7480-100","lead_sponsor":"BicycleTx Limited","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BT7480"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"a823c207-e7e1-4f29-8a31-680d49989ddd","acronym":"AVIATOR","url":"https://clinicaltrials.gov/study/NCT03414658","created_at":"2021-01-18T16:50:49.598Z","updated_at":"2025-02-25T13:52:30.920Z","phase":"Phase 2","brief_title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab \u0026 Utomilumab in Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT03414658 - AVIATOR","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-11-06"},{"id":"5d9e3655-cb50-477b-86ac-5e2e42b0f19d","acronym":"BP42675","url":"https://clinicaltrials.gov/study/NCT04826003","created_at":"2021-04-01T16:52:30.647Z","updated_at":"2024-07-02T16:34:37.780Z","phase":"Phase 1/2","brief_title":"Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment","source_id_and_acronym":"NCT04826003 - BP42675","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-06-06"},{"id":"8577f9f8-3299-4ebb-ba9e-c93e03ca96c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05523947","created_at":"2022-09-01T13:59:30.741Z","updated_at":"2024-07-02T16:34:37.982Z","phase":"Phase 1/2","brief_title":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","source_id_and_acronym":"NCT05523947","lead_sponsor":"Yuhan Corporation","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • nesfrotamig (ABL105)"],"overall_status":"Recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-05"},{"id":"e96ac04f-d494-4797-b71d-2048e4719923","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318900","created_at":"2021-01-18T16:23:25.179Z","updated_at":"2024-07-02T16:35:05.191Z","phase":"Phase 1/2","brief_title":"T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03318900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • PRAME • COL6A3","pipe":" | ","alterations":" PRAME expression","tags":["HLA-A • PRAME • COL6A3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-08"},{"id":"30f65fb4-2749-4fef-afce-463eb9f18dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046274","created_at":"2023-09-21T15:11:03.332Z","updated_at":"2024-07-02T16:35:06.914Z","phase":"Phase 2","brief_title":"GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer","source_id_and_acronym":"NCT06046274","lead_sponsor":"Genmab","biomarkers":" MSI • TIGIT","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-04-30"},{"id":"7a2a3b4c-52cf-4f7d-afea-af8fd4a47657","acronym":"","url":"https://clinicaltrials.gov/study/NCT03650348","created_at":"2021-01-18T17:54:56.686Z","updated_at":"2024-07-02T16:35:08.258Z","phase":"Phase 1","brief_title":"PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors","source_id_and_acronym":"NCT03650348","lead_sponsor":"Pieris Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cinrebafusp alfa (PRS-343)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 08/11/2022","primary_completion_date":" 08/11/2022","study_txt":" Completion: 08/11/2022","study_completion_date":" 08/11/2022","last_update_posted":"2024-04-22"},{"id":"6599101d-aea2-4fda-beb6-038d37252237","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440735","created_at":"2023-04-26T18:04:49.712Z","updated_at":"2024-07-02T16:35:11.822Z","phase":"Phase 1/2","brief_title":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04440735","lead_sponsor":"Kahr Medical","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DSP-107"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"},{"id":"0fa8ab04-e7a7-4cdf-a8ec-f0b54cef76dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04121676","created_at":"2022-01-21T18:55:54.943Z","updated_at":"2024-07-02T16:35:12.106Z","phase":"Phase 1","brief_title":"Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer","source_id_and_acronym":"NCT04121676","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e botensilimab (AGEN1181) • AGEN2373"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-04-01"},{"id":"66f13626-45a2-4288-b3f1-b38139944712","acronym":"NCI-2018-01118","url":"https://clinicaltrials.gov/study/NCT03217747","created_at":"2021-01-18T15:52:38.634Z","updated_at":"2024-07-02T16:35:12.950Z","phase":"Phase 1/2","brief_title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","source_id_and_acronym":"NCT03217747 - NCI-2018-01118","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 08/02/2017","start_date":" 08/02/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-25"},{"id":"80aeebc4-d0de-4187-be00-eb2d58e0ac3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04903873","created_at":"2021-05-27T13:53:05.902Z","updated_at":"2024-07-02T16:35:14.549Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04903873","lead_sponsor":"Eutilex","biomarkers":" ALK • MSI • ROS1","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["ALK • MSI • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EU101"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/31/2021","start_date":" 05/31/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"b7a36882-65b3-44a2-abdd-b0fe4500256d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03809624","created_at":"2021-07-22T21:52:31.520Z","updated_at":"2024-07-02T16:35:18.390Z","phase":"Phase 2","brief_title":"Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer","source_id_and_acronym":"NCT03809624","lead_sponsor":"Inhibrx, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enristomig (INBRX-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-21"},{"id":"ddf0452e-32bb-460c-8ff8-6fa35814d73e","acronym":"GNC-035-103","url":"https://clinicaltrials.gov/study/NCT05160545","created_at":"2021-12-16T13:53:38.176Z","updated_at":"2024-07-02T16:35:21.629Z","phase":"Phase 1","brief_title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05160545 - GNC-035-103","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nebratamig (GNC-035)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/26/2021","start_date":" 11/26/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-31"},{"id":"ef445441-1fa2-4ae0-902f-a212eb32e07a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05150405","created_at":"2021-12-09T18:00:08.188Z","updated_at":"2024-07-02T16:35:22.471Z","phase":"Phase 1","brief_title":"A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT05150405","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QL301"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-23"},{"id":"3a03b175-0fe2-4a87-abd3-94e44f7e3cc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04260802","created_at":"2021-01-18T20:42:20.349Z","updated_at":"2024-07-02T16:35:27.907Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","source_id_and_acronym":"NCT04260802","lead_sponsor":"Ocellaris Pharma, Inc.","biomarkers":" HER-2 • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion","tags":["HER-2 • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OC-001"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/06/2020","start_date":" 10/06/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-11-28"},{"id":"cbd3eb95-a6b5-4374-a565-cf5286d2e1ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05735366","created_at":"2023-02-21T16:01:47.196Z","updated_at":"2024-07-02T16:35:29.755Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05735366","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • SAIL66"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-11-09"},{"id":"60707de4-d68b-43d2-b8f8-d68e859d0321","acronym":"","url":"https://clinicaltrials.gov/study/NCT05301764","created_at":"2022-03-31T19:54:37.938Z","updated_at":"2024-07-02T16:35:37.037Z","phase":"Phase 1/2","brief_title":"A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma","source_id_and_acronym":"NCT05301764","lead_sponsor":"Lyvgen Biopharma Holdings Limited","biomarkers":" TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9","pipe":"","alterations":" ","tags":["TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • exlinkibart (LVGN6051)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 03/19/2025","primary_completion_date":" 03/19/2025","study_txt":" Completion: 10/19/2025","study_completion_date":" 10/19/2025","last_update_posted":"2023-09-14"}]